PHARMACEUTICAL COMPOSITION FOR PREVENTING, TREATING, AND CURING PSORIASIS INCLUDING SNAIL SLIME, CHAMOMILE, AND HONEY

Abstract

The invention relates to a pharmaceutical composition consisting of snail slime of Helix aspersa muller (Cryptophalus aspersus) (5% to 50%), chamomile extract (5% to 10%), honey (5% to 10%), and additives and/or pharmaceutically accepted excipients to form a formulation having low, intermediate or high viscosity (1 to 1000 Pa.Math.s). By dipping a patch or bandage of gauzy fabric into the composition in the form of a lotion, shampoo, soap, cream or gel, the composition is applied on lesions caused by psoriasis. The composition can also contain natural extracts, such as marigold extract, propolis, and vegetable oils. The invention also claims a method for obtaining the composition and the use thereof to prepare a drug or device for preventing, treating or curing psoriasis lesions on the head, the skin of the body or of the face.

Claims

1-13. (canceled)

14. A pharmaceutical composition for treating psoriasis lesions comprising: about 5-50 w % snail slime from Helix aspersa Muller (Cryptophalus asperses); about 5-10 w % chamomile extract; and about 5-10 w % honey; wherein said snail slime, chamomile extract and honey are dissolved in a base including one or more excipients, and said composition has a viscosity between 10-1000 Pa.Math.s.

15. The composition of claim 14 wherein said snail slime is limited to at most 20 w %.

16. The composition of claim 14 wherein said viscosity is limited to 500 Pa.Math.s.

17. The composition of claim 14 wherein said composition is embedded into a patch or bandage.

18. The composition of claim 14 wherein said composition is in the form of a lotion.

19. The composition of claim 14 wherein said composition is in the form of a shampoo.

20. The composition of claim 14 wherein said composition is in the form of a soap.

21. The composition of claim 14 wherein said composition is in the form of a cream or gel.

22. The composition of claim 14 wherein said composition further comprising at least one of nettle extract, calendula extract, and propolis.

23. A method for treating psoriasis lesions comprising the steps of: soaking a dressing in a solution, and applying the dressing to the wound; wherein said composition is comprised of about 5-50 w % snail slime from Helix aspersa Muller (Cryptophalus asperses); about 5-10 w % chamomile extract; and about 5-10 w % honey; said snail slime, chamomile extract and honey are dissolved in a base including one or more excipients, and said composition has a viscosity between 10-1000 Pa.Math.s.

24. The method of claim 23 wherein said snail slime is limited to at most 20 w %.

25. The method of claim 23 wherein said viscosity is limited to 500 Pa.Math.s.

26. The method of claim 23 wherein said composition is embedded into a patch or bandage.

27. The method of claim 23 wherein said composition is in the form of a lotion.

28. The method of claim 23 wherein said composition is in the form of a shampoo.

29. The method of claim 23 wherein said composition is in the form of a soap.

30. The method of claim 23 wherein said composition is in the form of a cream or gel.

31. The method of claim 23 wherein said composition further comprising at least one of nettle extract, calendula extract, and propolis.

32. A method of preparing a dressing for treating psoriasis lesions comprising the steps of: chilling a sterilized body cream base; adding about 5-50 w % by weight snail slime from Helix aspersa Muller (Cryptophalus asperses); about 5-10 w % by weight chamomile extract; and about 5-10 w% by weight honey; wherein said composition has a viscosity between 10-1000 Pa.Math.s.

33. The method of claim 32, where said dressing is a formed of gauze.

Description

DESCRIPTION OF THE FIGURES

[0061] FIG. 1: Photograph of Helix aspersa Miller snail strain

[0062] FIG. 2: Results of application of the patch-embedded product on arm skin with a seriologic episode. A) day 1 (box indicates mode of application of the patch), b) day 3, c) day 5, d) day 10.

[0063] FIG. 3: Shape and dimensions of the various gauze patches or gel-embedded bandages of the invention for therapeutic purposes.

REFERENCES

[0064] Abad R, Therapeutic and cosmetic compositions for treatment of skin, patente número 5538740, 1996.

[0065] Coto E, Santos-Juanes J, Coto-Segura P, Alvarez V. New soriasis susceptibility genes: momentum for skin-barrrier disruption. J Inves Dermatol. 2011 May: 131 (5): 1003-5.

[0066] De Korte J., Mombers F. M. C., Sprangers M. A. G. and J. D. Bos, The suitability of quality-of-life questionnaires for soriasis research: a systematic literature review, Arch Dermatol 138 (2002), pp. 1221-1227.

[0067] Denda S, Denda M, Inoue K, Hibino T. Glycolic acid induces keratinocyte proliferation in a skin equivalent model via TRPV1 activation. J DermatolSci. 2010 February; 57(2):108-13. Epub 2010 Jan. 8.

[0068] Elson M L. The molecular structure of glycolic acid and its importance in dermatology. Cosmetic Dermatology; 6(7): 35-40, 1993.

[0069] Farber E M. Studies on the nature and management of soriasis. Calif Med. 1971 June: 114 (6): 1-10.

[0070] Farley E, Menter A. Soriasis: Comorbidities and associations. G Ital Dermatol Venereol. 2011 February; 146(1):9-15.

[0071] Gupta M. A., Gupta A. K. and S. Kirby, A psychocutaneous profile of soriasis patients who are stress reactors, Gen Hosp Psych 11(1989), pp. 166-173. Abstract.

[0072] Hayes J, Koo J. Soriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther. 2010 March; 23(2):174-80.

[0073] Higgins E., Alcohol, smoking and soriasis, Clin Exp Dermatol 25 (2000), pp. 107-110.

[0074] Kurian A, Barankin B. Current effective topical therapies in the management of soriasis. Skin Therapy Lett. 2011 January; 16(1):4-7. Review.

[0075] Rapp S. R., Feldmann S. R., Exum M. L., Fleischer A. B. and D. M. Reboussin, Soriasis causes as much disability as other major medical diseases, J Am Acad Dermatol 41 (1999), pp. 401-407.

[0076] Sage E H & Gray W R 1977 Evolution of elastin and elastin structure, p 291. in; Advances in Experimental Medicine and Biology, vol. 79 LB Sandberg & C Franzblaw, eds) Plenum Press, NY & London).

[0077] Sznitowska M, Janicki S.The effect of vehicle on allantoin penetration into human skin from an ointment for improving scar elasticity. Pharmazie.1988 March; 43(3):218.

[0078] Tribó M J, Parrado C, Rais B et al. Preliminary results of the efficacy of intensive treatment with the secretion of Cryptomphalus aspersa (SCA) in phototherapy skin aging. Med CutanlberLat Am. 2004; 32:265-270.

[0079] Tsankov N, Botev-Zlatkov N, Lazarova A Z, Kostova M, Popova L, Tonev S. Soriasis and drugs: influence of tetracyclines on the course of soriasis. J Am Acad Dermatol. 1988 October; 19(4):629-32.

[0080] Tsankov N., Angelova I. and R. Kazandjieva, Drug-induced soriasis. Recognition and management, Am J Clin Dermatol 1(2000), pp. 159-165.

[0081] Turchin I, Adams S P. Demacase: soriasis. Can Fam Physician 52 (9): 1073, 1080 (2006 September).

[0082] Van de Kerkhof P C. Options for the treatment of soriasis: a multifactorial approach. Clin Dermatol. 2008 September-October; 26(5): 419-23.

[0083] Young G L, Jewell D. (2002). Creams for preventing stretch marks in pregnancy. Cochrane Database Syst Rev., (2): CD000066.